Gilead Sciences Inc

GILDNASDAQ · USD
167.58USD0.00 (-0.30%)
7510

Gilead Sciences Inc (GILD) Option Chain

Gilead Sciences Inc trades at $167.58, down 0.30%, with an IV Rank of 65.08%. This is average versus the past year, and the company carries a market cap of $207,856M in the Drug Manufacturers - General industry. On the Nov 20, 2026 chain, the at the money $167.50 strike shows calls at $2.35 / $2.95 and puts at $2.28 / $2.94, both carrying about $2.59 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $177.50 calls, at 85 contracts, and the $162.50 puts, at 36, as of Nov 16, 2026.

Read more

Tracking the GILD option chain helps you see every strike and expiry on Gilead Sciences Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of GILD options activity at a glance. Use our scanner to monitor the GILD option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For GILD stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where GILD options are being actively traded, and where they are not.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
17.2412330.895.085.656.30162.50-3.030.801.160.000.983622082.76
31.7611,055261.542.583.804.45165.00-1.541.451.880.001.671440668.24
49.5425682.570.082.352.95167.50-0.052.282.940.002.61820750.46
67.171,474201.660.001.341.98170.00+1.443.004.402.421.28144232.83
81.44324261.010.000.751.27172.50+2.943.957.304.920.71142618.56

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - General
  • SectorHealthcare
  • IV Rank65.08% Moderate
  • Market cap (M$)207,856
  • 52 weeks high-5.10%
  • 52 weeks low43.38%
  • Analyst recommendationBuy
    1.61
  • Target price$176.32
    5.22% above the current stock price
  • Dividend—
  • Payout ratio46.60%
  • Earnings date2027-02-09
  • P/E—
  • Future P/E16.51
  • EPS (ttm)-3.15
  • EPS growth next 5 years9.68%

As of Nov 16, 2026